Researchers Identify New Drug Target That Stimulates Beta Cell Regeneration

Researchers Identify New Drug Target That Stimulates Beta Cell Regeneration

September 06, 2011

– JDRF-funded scientists collaborate with pharmaceutical company to uncover new ways to stimulate pancreatic beta cell growth

Media Contact: Joana Casas, 212.479.7560, mcasas@jdrf.org

NEW YORK, N.Y., Sept. 6, 2011 — One of the holy grails in diabetes research is to discover molecules that stimulate beta cell growth and to find drugs that target these molecules. Now, JDRF-funded researchers in collaboration with the pharmaceutical company Hoffmann-La Roche, have done both, discovering not only a protein that regulates beta cell growth, but also a chemical compound that stimulates it. The work appears in the September 7 issue of Cell Metabolism.

The discovery, led by Markus Stoffel, M.D., Ph.D., a professor at the Swiss Federal Institute of Technology in Zurich, represents a significant advance in identifying a new drug target for beta cell regeneration.

The work builds on a discovery made five years ago, when Dr. Stoffel and his team first showed that a once obscure protein, called Tmem27, is localized on the surface membrane of beta cells, the insulin-producing cells that are located within islets in the pancreas. At the time, they found that increased levels of Tmem27 on beta cells were associated with increased islet mass in mice. They also found that if Tmem27 is cleaved, it left the protein completely inactivated.

“We hypothesized that if we could prevent Tmem27 from being cleaved and increase the levels of this protein, we could get more beta cell growth,” says Dr. Stoffel, who is also a 2010 recipient of JDRF’s Gerold & Kayla Grodsky Basic Research Scientist Award. “This observation gave us the rationale to look for what was inactivating Tmem27.”

After screening possible molecules that could snip Tmem27, Dr. Stoffel and his team found the culprit: Bace2, an enzyme protein that, like Tmem27, also resides on the outer surface (known as the plasma membrane) of the beta cell. The researchers confirmed their theory by finding that mice that lacked Bace2 had larger islets and the beta cells in the islets increased in number, a process known as proliferation or regeneration. They also found that these mice were able to clear glucose from the blood more efficiently than control mice with Bace2.

Dr. Stoffel and his team next aimed to inhibit Bace2 in an effort to control and promote the growth of beta cells. To do so, they teamed up with scientists at Hoffmann-LaRoche who developed a chemical compound that could inhibit Bace2. When the scientists gave this compound to mice, they saw that it inhibited Bace2 and stimulated the growth of new beta cells. Importantly, Bace2, and not its close relative Bace1, which is implicated in other diseases, cleaves the Tmem27 protein, suggesting the potential for developing a Bace2 inhibitor as a diabetes-specific therapy.

In addition to identifying a new drug target for promoting beta cell regeneration, Dr. Stoffel’s work may also help in developing tests to measure the amount of Tmem27 fragments in the blood – a biomarker that could be used as an index of beta cell number.

“This is an exciting and potentially impactful finding,” says Patricia Kilian, Ph.D., scientific program director of regeneration research at JDRF. “It’s an example of how researchers make an early observation and follow up on it, and then take it to the next level where it has translational potential – the potential to be developed into a drug that promotes the growth of beta cells for diabetes.”

 

 

 

About JDRF

JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.

Since its founding in 1970, JDRF has awarded more than $1.7 billion to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. More than 80 percent of JDRF’s expenditures directly support research and research-related education.